Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine ...
Nevakar, Inc.January 28, 2021 GMT
-- Potential to receive up to $135 million upon the successful attainment of several key regulatory and sales milestones --
BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17. It is currently under clinical evaluation in the CHAMP (Childhood Atropine for Myopia Progression) study, a Phase III clinical trial being carried out in the U.S. and Europe.